Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Kinetics of Immunoglobulins in Septic Shock Patients Treated With an IgM- and IgA-Enriched Intravenous Preparation: An Observational Study.
Berlot G, Scamperle A, Istrati T, Dattola R, Longo I, Chillemi A, Baronio S, Quarantotto G, Zanchi S, Roman-Pognuz E, Bixio M, Tomasini A. Berlot G, et al. Among authors: chillemi a. Front Med (Lausanne). 2021 Mar 1;8:605113. doi: 10.3389/fmed.2021.605113. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33732713 Free PMC article.
Correction to: Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients.
Berlot G, Vassallo MC, Busetto N, Yabar MN, Istrati T, Baronio S, Quarantotto G, Bixio M, Barbati G, Dattola R, Longo I, Chillemi A, Scamperle A, Iscra F, Tomasini A. Berlot G, et al. Among authors: chillemi a. Ann Intensive Care. 2019 Mar 5;9(1):33. doi: 10.1186/s13613-019-0504-0. Ann Intensive Care. 2019. PMID: 30838471 Free PMC article.
Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients.
Berlot G, Vassallo MC, Busetto N, Nieto Yabar M, Istrati T, Baronio S, Quarantotto G, Bixio M, Barbati G, Dattola R, Longo I, Chillemi A, Scamperle A, Iscra F, Tomasini A. Berlot G, et al. Among authors: chillemi a. Ann Intensive Care. 2018 Dec 10;8(1):122. doi: 10.1186/s13613-018-0466-7. Ann Intensive Care. 2018. PMID: 30535962 Free PMC article.
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.
Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein AL, Aversa F, Malavasi F, Giuliani N. Costa F, et al. Among authors: chillemi a. Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915615 Free PMC article.
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.
Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, Grignani G, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D. Mesiano G, et al. Among authors: chillemi a. Mol Med. 2017 Oct;23:235-246. doi: 10.2119/molmed.2017.00084. Epub 2017 Aug 9. Mol Med. 2017. PMID: 28805233 Free PMC article.
Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
D'Abundo L, Callegari E, Bresin A, Chillemi A, Elamin BK, Guerriero P, Huang X, Saccenti E, Hussein EMAA, Casciano F, Secchiero P, Zauli G, Calin GA, Russo G, Lee LJ, Croce CM, Marcucci G, Sabbioni S, Malavasi F, Negrini M. D'Abundo L, et al. Among authors: chillemi a. Oncogene. 2017 Nov 23;36(47):6617-6626. doi: 10.1038/onc.2017.269. Epub 2017 Aug 7. Oncogene. 2017. PMID: 28783166 Free article.
34 results